Shanghai, China, 12 December 2024 –The VitaFlow Liberty^® Transcatheter Aortic Valve and Retrievable Delivery System (VitaFlow Liberty^®), the second-generation transcatheter aortic valve implantation (TAVI) solution from MicroPort^® CardioFlow, has recently received marketing approval from the Korean Ministry of Food and Drug Safety (MFDS) (Registration No.: 수허 24-268 호).

VitaFlow Liberty^® is the world's first electric retrievable TAVI system. Building on the design strengths of its predecessor VitaFlow^®, it incorporates a hybrid-density self-expanding stent, bovine pericardial leaflets, and an advanced double-layer PET skirt. These features provide high radial support, enhance coaxial release, and significantly reduce the incidence of post-procedural paravalvular leaks. Furthermore, its groundbreaking upgraded delivery system features a unique double-reinforced spiral structure, enabling rapid, stable, and precise release and retrieval. This system also achieves flexibility, with the ability to bend the valve segment 360°, further enhancing surgical precision and adaptability.

The VitaFlow^® series TAVI solution, along with its accessory, the Alwide^® series Balloon Catheter (Alwide^® Plus), has been adopted by more than 700 hospitals across 20 countries and regions, benefiting over 10,000 patients with aortic valve diseases worldwide.